The efficacies of nine enzyme-linked immunOsorbent assays (EIA) for antibody to human Immunodeficiency virus type 1 (HIV-I) 8nd one EIA for antibody to HlV-2 Ln detecting antibody to HIV-2 were studied. The competitive EIAs for antibody to HIV-I were less selisitive than the indirect E I h . The overall prevalence of positive results was between 28 and 51% with the competitive EIAs and between 70 and 93% with the indirect EIAs. Most of the EIAs were less sensitive in detecting antibody to HIV-2 in sera from people with acquired immunodeficiency syndrome-like diseases than in sera from symptomless individuals. The results indicate that then is a high degree of cross-reactivity between HIV-1 and HIV-2 by EIA, indicating that serotype specificity must be determined by Western blot (immunoblot) with both sets of viral antigens. The results are relevant for discussing public health strategies, especially the screening of blood donors; competitive EIAs for antibody to HIV-1 are not sensitive enough to be used in areas where HIV-2 is prevalent (West Africa). 
positive results was between 28 and 51% with the competitive EIAs and between 70 and 93% with the indirect EIAs. Most of the EIAs were less sensitive in detecting antibody to HIV-2 in sera from people with acquired immunodeficiency syndrome-like diseases than in sera from symptomless individuals. The results indicate that then is a high degree of cross-reactivity between HIV-1 and HIV-2 by EIA, indicating that serotype specificity must be determined by Western blot (immunoblot) with both sets of viral antigens. The results are relevant for discussing public health strategies, especially the screening of blood donors; competitive EIAs for antibody to HIV-1 are not sensitive enough to be used in areas where HIV-2 is prevalent (West Africa). c A category of human retroviruses has been recently identified which is related to human immunodeficiency virus type 1 (HIV-1) but is more closely related to a group of simian retroviruses (STLV3BIV). These viruses, named HIV-2, formerly human T cell lymphotropic virus type IV (HTLV-IV) or lymphadenopathy-associated virus type 2 (LAV-2). are prevalent in West Africa and have been found occasionally in Europe (1, 4, 6, 9, 10, 11, 13. 18, 19, 21) .
There is a high degree of immunologic cross-reactivity between the gag gene products and the pol gene products of HIV-1 and HIV-2 (14. 9, 18). In contrast, the envelope glycoproteins that are the most frequently detected antigens by a9ibodies from exposed individuals are less cross-reactive. Knowing these cross-reactivities, we evaluated the efficacy of 10 enzyme immunoassays (EIAs) for antibody to HIV in detecting antibody to HIV-2 in sera from West African residents.
MATERIALS A N D METHODS
Sera. A total of 43 sera matching the original definition of sera positive for antibody to HIV-2 were used in this study (3.4, 18) . All these sera were cbllected in Ivory Coast during 1986; 23 sera were from symptomless individuals belonging to different risk groups, such as prostituteS. prisoners, or individuals suffering from a sexually transmitted disease, and 20 sera were from patients with acquired immunodeficiency syndrome (AIDS)-like diseases. These patients suffered mainly from a severe respiratory infection associated with weight loss (over 10% of body weight) in 18 cases (90%). profound asthenia in 18 cases (90%). and persistent diarrhea in 9 cases (45%).
Serotype specificity. Serotype specificity was determined by differential reactivity to envelope glycoproteins of HIV-1 and HIV-2 by using the Western blot (immunoblot) procedure as already described (3,*4, 18 
RESULTS
Representative Western blots of typical HIV-2-antibodypositive sera are shown in Fig. 1 . In addition to the transmembrane glycoprotein gp32, a smearing protein of approximately 68 kilodaltons resembling a glycoprotein was recognized by all the HIV-2-positive sera. This 68-kilodalton protein, which appears to be highly immunogenic, remains to be identified.
Sensitivities of the 10 assays in detecting antibody to HIV-2 are shown in Table 2 . The distribution patterns of responses in these EIAs, except for the Envacore from Abbott, are represented in (Table 2) . A total of 20 HIV-2-positive sera (47%) were positive for both envelope and core recombinant proteins of HIV-1 (Fig. 3) . and 13 (30%) were positive only for antibody to HIV-1 core recom- was also less sensitive in detecting cross-rcacting antibodies in sera from patients with AIDS-like discases than in sera from symptomless individuals ( Table 2 ).
The Elavia 2 assay that uses LAV-2 as the viral antigen detected 98% (42 of 43) of sera positive for antibody to HIV-2. One serum collected from a sick person was found repeatedly negative (absorbance value cutoff, 0.8). This serum contained only antibody to HIV-2 glycoproteins (Fig.  1, lane 6) . However, it was weakly positive in seven of the nine ElAs for antibody to HIV-I.
DISCUSSION.
This study shows that commercial HIV-1 antibody test kits are not equally efficient in detecting HIV-2-antibodypositive sera. Particularly, competitive ElAs are less sensitive than indirect EIAs. This conclusion confirms preliminary observations (7. 14) which indicated that cross-reacting HIV-2 antibodies do not have enough affinity to compete with the anti-HIV-1 conjugate. HIV-2-positive AIDS patients were reported not to have serological cross-reactivity which HIV-1 (8, 9). This is not confirmed by the present extensit:e study. Our study indicates that the indirect ElAs for antibody to HIV-1 detected from 50% (Organon-Teknika) to 95% (Ortho) of HIV-2-antibody-positive sera collected from patients with AIDS-like diseases. The competitive EIAs detected only from 5% (Wellcome) to 20 to 40% (Calbiochem-Behring) of the same HIV-2-antibody-positive sera. However, it is clear that most of the EIAs for antibody to HIV-1 were less sensitive in detecting antibody to HIV-2 in sera collected from sick people than in sera collected from It has been shown b j radioimmunoprccipitation and sodium dodecyl sulfate-polyacrylamide pel electrophoresis (RIP/SDS-PAGE) that HI V-1 and HIV-2 share epitopes in all the major viral antigens (18). T h e cross-reactivity is prominent for the gng-encodcd proteins, but it must be noted that some human sera may rccognizc both envelope glycoproteins with diflerential cfficacy on the basis of RIPISDS-PAGE analyses. In thc present study, w e demonstrate that 56% of people exposed to HIV-2 developed antibodies that cross-reacted with a recombinant-DNA-derived HIV-1 antigen from the c m region containing all aniino acids of gp41 a s well as a portion of g p l l 0 . This indicatcs that the Envacore assay did not allow a scrotype-specific diagnosis based on the recombinant envelopc protein of HIV-l. This observation has important impliìations. First, it confirms that antigens encoded by the w v genes of HIV-1 and HIV-2 are serologically cross-reaclive when nondenatured proteins, even those produced by recombinant technology. are used. Further characterization of these cross-reactive epilopes in t h e cnv-encoded proteins may be important for evaluation as subunits for a n AIDS vaccine. Second, care should be taken in interpreting serological diagnosis of HIV infections. A sensitive assay able to discriminate between antibodies t o HIV-1 envelope proteins and HIV-2 envelope proteins must be used. In this respect. Western blot seems to be very useful; antibody-positive sera give a strong signal with the transmembrane g l y c o p o t e i n of the corresponding serotype alone. RIPISDS-PAGE is more able to detect cross-reactive antibodies t o the em-encoded gp120 and gp160 (18). indicating that epitopes associ:ited with the primary structure of the transmembrane proteins a r e weakly conserved if at all between HIV-1 and HIV-2. However. some amino acid resUÚes important for t h e secondary and tertiary structures of the envelope proteins are conserved. Therefore, common or cross-reactive conformational epilopes, detecled by RIPISDS-PAGE but not b y Western blot, are conserved; they are present in etri. gene products of both viruses (16.
17).
It has been shown recently that it is possible to discriminate between antibodies to HIV-1 and antibodies to HIV-2 by using synthetic peptides located within the transmembrane glycoproteins of these related viruses (15, 20, 22).
These studies suggest that peptides of both conserved and nonconserved epitopes of t h e envelope glycoproteins of related H T L V s may be useful for specific diagnostic purposes.
O u r study presents data on the eficacy of 10 ElAs in detecting antibody to HIV-2. T h e results indicate that competitive EIAs for antibody to HIV-1 arc not sensitive enough to be used in areas whcre HIV-2 is prevalent (West Africa). In these areas, serotype specificity must be determined by immunoblot with both sets of viral antigens whether an indirect EIA for HIV-1 or for HIV-2 is used as a scrccning procedure.
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